-+ 0.00%
-+ 0.00%
-+ 0.00%

Can-Fite FY26 H1 net loss narrows 5.54% to USD 4.6 million

PUBT·09/08/2026 12:20:25
Listen to the news
Can-Fite FY26 H1 net loss narrows 5.54% to USD 4.6 million
  • Can-Fite posted a GAAP net loss of USD 4.6 million for the six months ended June 30, narrowing 5.54%.
  • Research and development expense climbed 13.86% to USD 3.45 million, due to accelerated Namodenoson and Piclidenoson program spending.
  • General and administrative costs fell 31.4% to USD 1.42 million on lower investor relations expense; revenue was flat at USD 202,000.
  • Cash, cash equivalents and short-term deposits totaled USD 7.03 million; September warrant exercises and inducement added about USD 4 million gross.
  • Pivotal Phase 3 psoriasis interim analysis results are expected in Q1 2027; blinded overall survival in Phase 3 liver cancer study appears longer than assumed.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Can Fite Biofpharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609080820PRIMZONEFULLFEED9822777) on September 08, 2026, and is solely responsible for the information contained therein.